New therapeutic approaches and prognostic factors in chronic myeloid leukemia. - Wikidata - awgldk - TriplyDB

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37132857

about

Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis.Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.Dasatinib Induced Cardiac Tamponade-A Rare Association.Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

P2860

Q33766467-5376257E-D6E7-4AF6-9123-254D40A6BD02 Q34451624-86ECAF70-9F9D-496C-802A-9108172D7725 Q37421579-AA10F12E-0182-4A3D-8137-EBEBC3816650 Q37709467-9DAD14A4-D0B5-4B8D-A4D4-B3FF4D1B485B Q42293055-E445750C-B1AF-4A32-AFB3-1F1E6CF6E2F3 Q48010780-EA0D6646-BBD9-4C8F-BA52-206EB1E04645 Q51373837-F8304807-DCAE-4DBD-BE6B-CDCD5CDC099A

P2860

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

http://www.wikidata.org/entity/Q37132857

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

@en

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

@nl

type

label

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

@en

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

@nl

prefLabel

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

@en

New therapeutic approaches and prognostic factors in chronic myeloid leukemia.

@nl

P1433

Q37132857-78E27F12-2A33-413E-B200-A290ADD182F9

P1476

Q37132857-779610D1-F435-4DC3-8E8D-F667BFA96711

P2093

Q37132857-139306FD-2860-4DA5-A77C-A056E2DFFF99

Q37132857-740B8FB5-C939-417B-B0D5-2086A7915354

Q37132857-95AD6808-E6FA-4A8C-BDE7-81B117B35CB2

Q37132857-C98A047E-12E9-4BF7-9867-2E0B2EAE7392

P2860

Q37132857-0BE9DA4C-67C6-481E-BBB0-DE2F3E1B49BE

Q37132857-5DA994CD-FABA-47B7-A714-1CC370427353

Q37132857-66A28F32-9ABD-4B26-AA7B-9DF7668031B7

Q37132857-76194E06-65D4-4115-947E-85B6F6C38D14

Q37132857-88DF7DA2-2712-4745-BF2E-53AA805B830A

Q37132857-8EEFF21A-5C6C-446B-94BC-0FE0EEE9D317

Q37132857-A433180E-8655-4927-B51E-5A651D6AFAA9

Q37132857-AA85E3C3-616A-420F-87D2-B3CB29DCCE56

Q37132857-C3A2024B-6900-4F52-80BB-C816748EBF30

Q37132857-F8531019-E25A-4E3F-92FA-7157B7878FB2

P304

Q37132857-D321DB39-4F03-4D78-8509-BAFE3F5ECF00

P31

Q37132857-A1C584B6-DDB1-4E44-80BB-D067A2438198

P356

Q37132857-1DAE050C-B398-498C-84FD-0E8FEA252ECC

P433

Q37132857-0CA5DBE5-FD9F-4DF9-813B-179892091C28

P478

Q37132857-EEE34419-FA18-4C3B-A490-FC36D41FDEAB

P50

Q37132857-7695F1C0-7332-4B7A-BA43-7410E07582BE

P577

Q37132857-7A47065B-E9CF-4939-83D2-DC10F6A8C15A

P698

Q37132857-290AF00E-107D-448D-8FEC-7AF1D0AE73D0

P921

Q37132857-0A2CB01D-B59D-41F4-8EB6-547F1EBCBDFF

Q37132857-E72AB73D-AA15-40C9-B630-66683CD440CE

P356

10428190801896210

P1433

Leukemia & Lymphoma

P1476

New therapeutic approaches and prognostic factors in chronic myeloid leukemia

@en

P2093

Daniela Cilloni

http://www.w3.org/2001/XMLSchema#string

Giovanna Rege-Cambrin

http://www.w3.org/2001/XMLSchema#string

Marco Bosa

http://www.w3.org/2001/XMLSchema#string

Stefano Ulisciani

http://www.w3.org/2001/XMLSchema#string

P2860

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Clonal evolution in chronic myelogenous leukemia.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Fusion tyrosine kinases: a result and cause of genomic instability.

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia

P304

625-628

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190801896210

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Saglio

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18398722

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia